AMPK in the small intestine in normal and pathophysiological conditions

Endocrinology

Volumn 155, Issue 3, 2014, Pages 873-888

  Harmel, Elodie ^a,b,e   Grenier, Emilie ^a,b   Ouadda, Ali Bendjoudi ^a   El Chebly, Mounib ^a,b   Ziv, Ehud ^c   Beaulieu, Jean François ^d   Sané, Alain ^a   Spahis, Schohraya ^a,b   Laville, Martine ^e   Levy, Emile ^a,b,d  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITÉ DE SHERBROOKE   (Canada)

^e UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; AMP KINASE ALPHA1; CARNITINE PALMITOYLTRANSFERASE I; GLUCOSE; GLYCOGEN SYNTHASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PSAMMOMYS OBESUS; RAT; SIGNAL TRANSDUCTION; SMALL INTESTINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTIOXIDANTS; CACO-2 CELLS; CARNITINE O-PALMITOYLTRANSFERASE; DIMERIZATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GERBILLINAE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN; INSULIN RESISTANCE; INTESTINE, SMALL; LIPID METABOLISM; LIPID PEROXIDATION; MALE; MAP KINASE SIGNALING SYSTEM; METFORMIN; MICROSOMES; ORGAN CULTURE TECHNIQUES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 84896858573     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1750     Document Type: Article

References (55)

1. Gao G, Fernandez CS, Stapleton D, et al. Non-catalyticß- and γ-subunit isoforms of the 5′-AMP-activated protein kinase. J Biol Chem. 1996;271:8675-8681.
2. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774-785. (Pubitemid 47462132)
3. Kemp BE, Stapleton D, Campbell DJ, et al. AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans. 2003;31: 162-168. (Pubitemid 36241420)
4. Wojtaszewski JF, Jørgensen SB, Hellsten Y, Hardie DG, Richter EA. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes. 2002;51:284-292. (Pubitemid 34764782)
5. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 1998;47: 1369-1373. (Pubitemid 28357021)
6. Carling D, Hardie DG. The substrate and sequence specificity of the AMP-activated protein kinase. Phosphorylation of glycogen synthase and phosphorylase kinase. Biochim Biophys Acta. 1989;1012: 81-86. (Pubitemid 19154923)
7. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006;47:1281-1288. (Pubitemid 43830720)
8. Chen MB, McAinch AJ, Macaulay SL, et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005;90:3665-3672. (Pubitemid 41014341)
9. Dolinsky VW, Dyck JR. Role of AMP-activated protein kinase in healthy and diseased hearts. AmJ Physiol Heart Circ Physiol. 2006; 291:H2557-H2569. (Pubitemid 44911033)
10. Zang M, Zuccollo A, Hou X, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem. 2004;279:47898-47905. (Pubitemid 39540941)
11. Zang M, Xu S, Maitland-Toolan KA, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006;55:2180-2191. (Pubitemid 44743614)
12. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25. (Pubitemid 43960587)
13. Ruderman NB, Saha AK, Kraegen EW. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology. 2003; 144:5166-5171. (Pubitemid 37476042)
14. Zong H, Ren JM, Young LH, et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA. 2002;99:15983-15987. (Pubitemid 35462735)
15. Hsieh J, Hayashi AA, Webb J, Adeli K. Postprandial dyslipidemia in insulin resistance: mechanisms and role of intestinal insulin sensitivity 1. Atheroscler Suppl. 2008;9:7-13.
16. Adeli K, Lewis GF. Intestinal lipoprotein overproduction in insulin-resistant states. Curr Opin Lipidol. 2008;19:221-228. (Pubitemid 351653558)
17. Grenier E, Maupas FS, Beaulieu JF, et al. Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion, and apolipoprotein biogenesis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G1178-G1189. (Pubitemid 350255043)
18. Levy E, Stan S, Delvin E, et al. Localization of microsomal triglyceride transfer protein in the Golgi: possible role in the assembly of chylomicrons. J Biol Chem. 2002;277:16470-16477. (Pubitemid 34967660)
19. Levy E, Spahis S, Ziv E, et al. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia. 2006;49:1937-1945. (Pubitemid 44025049)
20. Levy E, Lalonde G, Delvin E, et al. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology. 2010;151: 958-970.
21. Zoltowska M, Ziv E, Delvin E, et al. Circulating lipoproteins and hepatic sterol metabolism in Psammomys obesus prone to obesity, hyperglycemia and hyperinsulinemia. Atherosclerosis. 2001;157: 85-96. (Pubitemid 32539357)
22. Zoltowska M, Ziv E, Delvin E, et al. Cellular aspects of intestinal lipoprotein assembly in Psammomys obesus: a model of insulin resistance and type 2 diabetes. Diabetes. 2003;52:2539-2545. (Pubitemid 37210543)
23. Zoltowska M, Ziv E, Delvin E, Lambert M, Seidman E, Levy E. Both insulin resistance and diabetes in Psammomys obesus upregulate the hepatic machinery involved in intracellular VLDL assembly. Arterioscler Thromb Vasc Biol. 2004;24:118-123. (Pubitemid 38082421)
24. Levy E, Thibault L, Ménard D. Intestinal lipids and lipoproteins in the human fetus: modulation by epidermal growth factor. J Lipid Res. 1992;33:1607-1617.
25. Levy E, Ménard D, Delvin E, et al. The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants. J Biol Chem. 2001;276:39679-39684.
26. Levy E, Marcel Y, Deckelbaum RJ, et al. Intestinal apoB synthesis, lipids, and lipoproteins in chylomicron retention disease. J Lipid Res. 1987;28:1263-1274. (Pubitemid 18007163)
27. Montoudis A, Seidman E, Boudreau F, et al. Intestinal fatty acid binding protein regulates mitochondrion β-oxidation and cholesterol uptake. J Lipid Res. 2008;49:961-972.
28. Ben Djoudi Ouadda A, Levy E, Ziv E, et al. Increased hepatic lipogenesis in insulin resistance and type 2 diabetes is associated with AMPK signalling pathway up-regulation in Psammomys obesus. Biosci Rep. 2009;29:283-292.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) method. Methods. 2001;25:402-408. (Pubitemid 34164012)
30. Santini SA, Marra G, Giardina B, et al. Defective plasma antioxidant defenses and enhanced susceptibility to lipid peroxidation in uncomplicated IDDM. Diabetes. 1997;46:1853-1858. (Pubitemid 27456421)
31. Kim YS, Kolattukudy PE. Malonyl-CoA decarboxylase from the uropygial gland of waterfowl: purification, properties, immunological comparison, and role in regulating the synthesis of multimethyl-branched fatty acids. Arch Biochem Biophys. 1978;190:585-597. (Pubitemid 9037850)
32. Ruderman NB, Saha AK, Vavvas D, Witters LA. Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol. 1999;276:E1-E18. (Pubitemid 29065588)
33. Mora A, Sakamoto K, McManus EJ, Alessi DR. Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett. 2005;579:3632-3638. (Pubitemid 40897703)
34. McManus EJ, Sakamoto K, Armit LJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 2005;24:1571-1583. (Pubitemid 40646447)
35. Birk JB, Wojtaszewski JF. Predominant α2/β2/γ3 AMPK activation during exercise in human skeletal muscle. J Physiol. 2006;577: 1021-1032. (Pubitemid 44873663)
36. Stapleton D, Woollatt E, Mitchelhill KI, et al. AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location. FEBS Lett. 1997;409:452-456. (Pubitemid 27285904)
37. Cheung PC, Salt IP, Davies SP, Hardie DG, Carling D. Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding. Biochem J. 2000;346(Pt. 3):659-669. (Pubitemid 30171026)
38. Moffat C, Ellen Harper M. Metabolic functions of AMPK: aspects of structure and of natural mutations in the regulatory γ subunits. IUBMB Life. 2010;62:739-745.
39. Salt I, Celler JW, Hawley SA, et al. AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J. 1998;334 (Pt 1):177-187. (Pubitemid 28420987)
40. Field FJ, Erickson SK, Shrewsbury MA, Cooper AD. 3-Hydroxy-3- methylglutaryl coenzyme A reductase from rat intestine: subcellular localization and in vitro regulation. J Lipid Res. 1982;23:105-113. (Pubitemid 12112618)
41. Oku H, Ide T, Sugano M. Reversible inactivation-reactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase of rat intestine. J Lipid Res. 1984;25:254-261. (Pubitemid 14165025)
42. Roduit R, Nolan C, Alarcon C, et al. A role for the malonyl-CoA/ long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes. 2004;53:1007-1019. (Pubitemid 38436613)
43. Zhu S, Sun F, Li W, et al. Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem. 2011;353:305-313.
44. Farese RV, Sajan MP, Standaert ML. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Exp Biol Med (Maywood). 2005;230:593-605. (Pubitemid 41506854)
45. Bozulic L, Hemmings BA. PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol. 2009;21:256-261.
46. White MF. Insulin signaling in health and disease. Science. 2003; 302:1710-1711. (Pubitemid 37505726)
47. Sundqvist A, Bengoechea-Alonso MT, Ye X, et al. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005;1:379-391. (Pubitemid 43960622)
48. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705-712.
49. Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrine. 2003;20:215-218. (Pubitemid 36571021)
50. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab. 2004;89:5043-5047. (Pubitemid 39391446)
51. Gauthier MS, O'Brien EL, Bigornia S, et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun. 2011; 404:382-387.
52. Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage α1 AMP-activated protein kinase (α1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 2010;285:19051-19059.
53. Bai A, Ma AG, Yong M, et al. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol. 2010;80:1708-1717.
54. Wu X, Mahadev K, Fuchsel L, Ouedraogo R, Xu SQ, Goldstein BJ. Adiponectin suppresses IκB kinase activation induced by tumor necrosis factor-α or high glucose in endothelial cells: role of cAMP and AMP kinase signaling. Am J Physiol Endocrinol Metab. 2007;293: E1836-E1844. (Pubitemid 350258452)
55. Kajita K, Mune T, Ikeda T, et al. Effect of fasting on PPARγ and AMPK activity in adipocytes. Diabetes Res Clin Pract. 2008;81: 144-149.